# Amwise Diagnostic PTE. LTD.

> Amwise Diagnostic is a Singapore- and Taipei-based cancer genomics company behind RecurIndex, a multi-gene test built specifically on the genomes of Asian breast cancer patients. It reads a tumor's genetic profile alongside clinical factors to estimate the five-year risk of local recurrence and distant metastasis, helping physicians and patients decide whether chemotherapy or radiotherapy is actually needed - and helping many avoid treatment they don't.

- **Founded:** 2015
- **Headquarters:** Singapore (R&D and operations in Taipei, Taiwan)
- **Founders:** Sean-Lin Huang (Founder & CEO)
- **Team size:** Small core team (public records list ~3), with operations spanning Singapore, Taipei, and Mainland China
- **Products:** RecurIndex (瑞可盈), RecurIndex - colorectal and other tumors (in development)
- **Notable:** Developed RecurIndex, one of the first breast cancer recurrence tests built and validated specifically on Asian genomes, Named a Top 10 BioTech Startup in APAC (2021) by Life Sciences Review APAC, US trademark registration for RECURINDEX (filed 2017)

## Products & services

- **RecurIndex (瑞可盈)** — A multi-gene (28-gene) prognostic test that combines genetic profiling of recurrence-relevant genes with clinical factors (age, tumor size, receptor status) to predict the 5-year risk of local recurrence (RI-LR) and distant metastasis (RI-DR) in early-stage breast cancer, developed and validated on Asian patients.
- **RecurIndex - colorectal and other tumors (in development)** — Research expanding the RecurIndex approach into colorectal, ovarian, and pancreatic cancers to extend recurrence and treatment-guidance testing to more cancer types.

## Achievements

- Developed RecurIndex, one of the first breast cancer recurrence tests built and validated specifically on Asian genomes
- Named a Top 10 BioTech Startup in APAC (2021) by Life Sciences Review APAC
- US trademark registration for RECURINDEX (filed 2017)
- Validated across roughly 20 clinical studies in Asia, including the prospective multicenter APRIL trial
- Peer-reviewed evidence in journals including Scientific Reports and Cancer Management and Research, including cost-effectiveness analysis
- Raised $10M+ from investors including Alibaba, WI Harper, Lippo Group, and Simcere

## Latest updates

- **2025-06** — APRIL trial results presented, showing RecurIndex predicts recurrence risk in early-stage luminal breast cancer.
- **2022-03** — Peer-reviewed cost-effectiveness analysis of RecurIndex published for HR-positive, HER2-negative early-stage breast cancer.
- **2021-04** — Study in Scientific Reports validates RecurIndex for prognosis in Chinese male breast cancer patients.
- **2020-02** — Closed $10M Series B led by Jiangsu Simcere Medical Diagnosis.

## Links

- Website: https://www.recurindex.com
- LinkedIn: https://www.linkedin.com/company/amwise-diagnostic

---

Profile page: https://yespress.io/amwise-diagnostic-pte-ltd
Published by YesPress — https://yespress.io
Last updated: 2026-08-04